Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

被引:165
作者
Suh, Jung-Won
Koo, Bon-Kwon
Zhang, Shu-Ying
Park, Kyung-Woo
Cho, Joo-Youn
Jang, In-Jin
Lee, Dong-Soon
Sohn, Dae-Won
Lee, Myoung-Mook
Kim, Hyo-Soo
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul 110744, South Korea
[4] Seoul Natl Univ Hosp, Clin Res Inst, Cardiovasc Lab, Seoul 110744, South Korea
关键词
D O I
10.1503/cmaj.060664
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A ( CYP(3)A) isoenzymes, including CYP3A5, in order to be active. It is controversial whether clopidogrel interacts with CYP3A inhibitors. We investigated the influence of CYP3A5 polymorphism on the drug interaction of clopidogrel. Methods: In phase 1 of the study, we administered clopidogrel to 16 healthy volunteers who had the CYP3A5 nonexpressor genotype (*3 allele) and 16 who had the CYP3A5 expressor genotype (*1 allele) with and without pretreatment with itraconazole, a potent CYP3A inhibitor. A platelet aggregation test was performed at baseline, 4 hours, 24 hours and 6 days after clopidogrel administration. In phase 2, we compared clinical outcomes of 348 patients treated with clopidogrel after successful coronary angioplasty with bare-metal stent implantation according to their CYP3A5 genotype; the primary end point was a composite of atherothrombotic events ( cardiovascular death, myocardial infarction and non-hemorrhagic stroke) within 1 and 6 months after stent implantation. Results: In phase 1, the change in platelet aggregation after clopidogrel administration and pretreatment with itraconazole was greater among the subjects with the CYP3A5 expressor genotype than among those with the non-expressor genotype: 24.9% ( standard deviation [ SD] 13.9%) v. 6.2% ( SD 13.5%) at 4 hours ( p < 0.001); 27.7% ( SD 16.5%) v. 2.5% ( SD 8.3%) at 24 hours ( p < 0.001); and 33.5% ( SD 18.6%) v. 17.8% ( SD 13.8%) at day 7 ( p < 0.01). In phase 2, atherothrombotic events occurred more frequently within 6 months after stent implantation among the patients with the non-expressor genotype than among those with the expressor genotype ( 14/193 v. 3/155; p = 0.023). Multivariable analysis showed that the CYP3A5 polymorphism was a predictor of atherothrombotic events in clopidogrel users. Interpretation: People with the CYP3A5 non-expressor genotype are vulnerable to drug interactions between clopidogrel and CYP3A inhibitors. This phenomenon may be associated with worse outcomes in patients with the non-expressor genotype who are given clopidogrel after coronary angioplasty and implantation of bare-metal stents.
引用
收藏
页码:1715 / 1722
页数:8
相关论文
共 32 条
[1]   CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations [J].
Balram, C ;
Zhou, QY ;
Cheung, YB ;
Lee, EJD .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) :123-126
[2]   ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
CIRCULATION, 2002, 106 (14) :1893-1900
[3]   The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J].
Clarke, TA ;
Waskell, LA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :53-59
[4]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[5]   Implications of cytochrome P450 interactions when prescribing medication for hypertension [J].
Flockhart, DA ;
Tanus-Santos, JE .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (04) :405-412
[6]   Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects [J].
Fontana, P ;
Dupont, A ;
Gandrille, S ;
Bachelot-Loza, C ;
Reny, JL ;
Aiach, M ;
Gaussem, P .
CIRCULATION, 2003, 108 (08) :989-995
[7]   Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population [J].
Fukuen, S ;
Fukuda, T ;
Maune, H ;
Ikenaga, Y ;
Yamamoto, I ;
Inaba, T ;
Azuma, J .
PHARMACOGENETICS, 2002, 12 (04) :331-334
[8]  
Gawaz M, 2000, THROMB HAEMOSTASIS, V83, P915
[9]   Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].
Gurbel, PA ;
Bliden, KP ;
Hiatt, BL ;
O'Connor, CM .
CIRCULATION, 2003, 107 (23) :2908-2913
[10]   Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population [J].
Hiratsuka, M ;
Takekuma, Y ;
Endo, N ;
Narahara, K ;
Hamdy, SI ;
Kishikawa, Y ;
Matsuura, M ;
Agatsuma, Y ;
Inoue, T ;
Mizugaki, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (06) :417-421